Temsirolimus: In Relapsed and/or Refractory Mantle Cell Lymphoma

By Hoy Sheridan M.   McKeage Kate  

Drugs, Vol. 70, Iss. 14, 2010-10 ,pp. : 1819-1829

Adis International

Access to resources Recommend Favorite

Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphoma

By Prichard Mark   Harris Thomas   Williams Michael E   Densmore John J  

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 6, 2009-04 ,pp. : 983-995

Informa Healthcare

Access to resources Recommend Favorite

Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma

By Kang Byung   Kim Won   Kim Chul   Jang Geundoo   Lee Sung   Choi Yoon   Lee Dae   Kim Sang   Kim Shin   Ryu Jin-Sook   Huh Jooryung   Lee Jung   Suh Cheolwon  

Investigational New Drugs, Vol. 28, Iss. 4, 2010-08 ,pp. : 516-522

Springer Publishing Company

Access to resources Recommend Favorite

Oncologic, Endocrine & Metabolic Emerging drugs in B-cell non-Hodgkin's lymphoma

By Kassam Shireen   Montoto Silvia  

Expert Opinion on Emerging Drugs, Vol. 13, Iss. 2, 2008-06 ,pp. : 323-343

Informa Healthcare

Access to resources Recommend Favorite

New agents and approaches to the treatment of B-cell non-Hodgkin lymphoma

By Burton Jack D   Goldenberg David M  

Expert Opinion on Emerging Drugs, Vol. 15, Iss. 4, 2010-12 ,pp. : 569-583

Informa Healthcare

Access to resources Recommend Favorite